Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;37(7):2245-2256.
doi: 10.1007/s11011-022-00939-0. Epub 2022 Apr 20.

Evolving therapies in neuronopathic LSDs: opportunities and challenges

Deepa S Rajan  1 , Maria L Escolar  2
Affiliations
Review

Evolving therapies in neuronopathic LSDs: opportunities and challenges

Deepa S Rajan et al. Metab Brain Dis. 2022 Oct.

Abstract

Lysosomal storage disorders (LSD) are multisystemic progressive disorders caused by genetic mutations involving lysosomal function. While LSDs are individually considered rare diseases, the overall true prevalence of these disorders is likely higher than our current estimates. More than two third of the LSDs have associated neurodegeneration and the neurological phenotype often defines the course of the disease and treatment outcomes. Addressing the neurological involvement in LSDs has posed a significant challenge in the rapidly evolving field of therapies for these diseases. In this review, we summarize current approaches and clinical trials available for patients with neuronopathic lysosomal storage disorders, exploring the opportunities and challenges that have emerged with each of these.

Keywords: Enzyme replacement therapy; Gene therapy; Hematopoietic stem cell therapy; Lysosomal storage disorders (LSDs); Neurodegeneration; Substrate reduction therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ballabio A, Bonifacino JS (2020) ‘Lysosomes as dynamic regulators of cell and organismal homeostasis’. Nat Rev Mol Cell Biol 21:101–118 - PubMed - DOI
    1. Barker JN, Weisdorf DJ, Wagner JE (2001) ‘Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors’. N Engl J Med 344:1870–1871 - PubMed - DOI
    1. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE et al (1991) ‘Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease’. N Engl J Med 324:1464–1470 - PubMed - DOI
    1. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) ‘Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease’. Proc Natl Acad Sci U S A 87:1913–1916 - PubMed - PMC - DOI
    1. Bellettato CM, Scarpa M (2018) ‘Possible strategies to cross the blood-brain barrier’. Ital J Pediatr 44:131 - PubMed - PMC - DOI

LinkOut - more resources